Researchers at The University of Edinburgh have developed tiny chemical sensors comprose of gold-coated particles that could help diagnose disease and track its progress.
Suspecting that a particular protein in tuberculosis was likely to be vital to the bacteria’s survival, Johns Hopkins scientists screened 175,000 small chemical compounds and identified a potent class of compounds that selectively slows down this protein’s activity.
Merck KGaA announced that Erbitux (cetuximab) can now be used in Japan in combination with chemotherapy in the first-line-treatment for patients with epidermal growth factor receptor (EGFR)-expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer (mCRC) carrying the KRAS wildtype gene.
A Phase 2 clinical trial for a promising treatment for diabetic eye disease has begun enrolling participants.
Two people with compromised immune systems who became ill with 2009 H1N1 influenza developed drug-resistant strains of virus after less than two weeks on therapy, report doctors from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Celerion, a privately owned contract research organization, has completed the acquisition of the development and regulatory services consultancy and early stage development operations of MDS Pharma Services.
The factors instrumental in triggering latent tuberculosis (TB) infection to progress into active disease have long remained elusive to researchers.
Pathogenic bacteria in the gut recognise their surroundings by detecting hormone signals from the host, which can prompt them to express lethal toxins.
Researchers at Children's Hospital Boston have identified a new strategy for treating type 2 diabetes, identifying a cellular pathway that fails when people become obese.
Daily administration of a cheap, widely available, antibiotic (co-trimoxazole) as prophylaxis halves mortality in severely immunosuppressed HIV-infected adults starting treatment in Africa; with benefits continuing for at least 72 weeks.
BioSeek, LLC, a subsidiary of Asterand plc, a pioneer in the application of predictive human biology to drug discovery, and Ono Pharmaceutical Co., Ltd., an R&D-oriented global specialty pharmaceuticals company, have signed a new multi-year drug discovery collaboration agreement.
Thermo Fisher Scientific Inc. launched a software-as-a-service (SaaS), enterprise-class laboratory information management system, LIMS-on-Demand.
A research team has demonstrated a specialized mapping technique that could speed work in genomic fields by quickly finding genetic associations that shape an organism's observable characteristics.
Illumina, Inc.'s HiSeq 2000 sequencing system generates two billion paired-end reads and 200 gigabases (Gb) of quality filtered data in a single run.